Latest News
Puma Biotechnology's Licensing Partner Knight Therapeutics Receives Regulatory Approval from Health Canada to Commercialise Nerlynx for Extended Adjuvant Treatment of Hormone Receptor Positive, HER2-Positive Early Stage Breast Cancer
18 July 2019 - - US-based Puma biotechnology, Inc. (NASDAQ: PBYI) licensing partner Knight Therapeutics Inc. (Knight) has received marketing authorisation from Health Canada to commercialise Nerlynx (neratinib) in Canada for the extended adjuvant tre...
FDA Approves US Merck's Recarbrio for the Treatment of Adults with Complicated Urinary Tract and Complicated Intra-Abdominal Bacterial Infections Where Ltd. or No Alternative Treatment Options Are Available
18 July 2019 - - The US Food and Drug Administration has approved Recarbrio (imipenem, cilastatin, and relebactam) for injection, 1.25 grams, a new combination antibacterial, US-based pharmaceutical company Merck (NYSE: MRK) said.
Recarbrio is ...
Pandion Therapeutics Names Kakkar as Chief Executive Officer
18 July 2019 - - US-based biotechnology company Pandion Therapeutics, Inc has appointed Rahul Kakkar, MD, FACC as chief executive officer and as a member of the company's board of directors, the company said.
Kakkar is a biotech entreprene...
Intensity Therapeutics' INT230-6 Induces Immune Activation by Intratumoral Delivery as Reported in the Peer-Reviewed Journal OncoImmunology
18 July 2019 - - The journal OncoImmunology has published results from nonclinical research conducted by US-based biotechnology company Intensity Therapeutics, Inc in partnership with the National Cancer Institute's Vaccine Branch unde...
PureTech Acquires New Clinical-Stage Program LYT-100 to Treat Lymphedema
18 July 2019 - - UK-based biopharmaceutical company PureTech Health plc (LSE: PRTC) has acquired and plans to develop a clinical-stage product candidate for the potential treatment of lymphatic and immunofibrotic diseases, including lymphedema, the c...